The potential mechanisms of berberine in the treatment of nonalcoholic fatty liver disease

Molecules

Volumn 21, Issue 10, 2016, Pages

  Zhu, Xiaopeng ^a   Bian, Hua ^a   Gao, Xin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Adenosine Monophosphate Activated Protein Kinase; Berberine; Insulin Resistance; Mechanism; Nonalcoholic Fatty Liver Disease

Indexed keywords

BERBERINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ANIMAL; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INSULIN RESISTANCE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BERBERINE; CLINICAL TRIALS AS TOPIC; DNA DAMAGE; GENE EXPRESSION REGULATION; HUMANS; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84992364749     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21101336     Document Type: Review

References (86)

1. Cohen, J.C.; Horton, J.D.; Hobbs, H.H. Human fatty liver disease: Old questions and new insights. Science 2011, 332, 1519-1523.
2. Kotronen, A.; Yki-Jarvinen, H. Fatty liver: A novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 27-38.
3. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-Alcoholic fatty liver disease: Practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association. Hepatology 2012, 55, 2005-2023.
4. Vanni, E.; Bugianesi, E.; Kotronen, A.; de Minicis, S.; Yki-Jarvinen, H.; Svegliati-Baroni, G. From the metabolic syndrome to NAFLD or vice versa? Dig. Liver Dis. 2010, 42, 320-330.
5. Younossi, Z.M.; Otgonsuren, M.; Henry, L.; Venkatesan, C.; Mishra, A.; Erario, M.; Hunt, S. Association of non-Alcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the united states from 2004-2009. Hepatology 2015, 62, 1723-1730.
6. Mittal, S.; El-Serag, H.B. Epidemiology of hepatocellular carcinoma: Consider the population. J. Clin. Gastroenterol. 2013, 47.
7. Mittal, S.; El-Serag, H.B.; Sada, Y.H.; Kanwal, F.; Duan, Z.G.; Temple, S.; May, S.B.; Kramer, J.R.; Richardson, P.A.; Davila, J.A. Hepatocellular carcinoma in the absence of cirrhosis in united states veterans is associated with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2016, 14, 124-131.
8. Kanwal, F.; Kramer, J.R.; Duan, Z.G.; Yu, X.Y.; White, D.; El-Serag, H.B. Trends in the burden of nonalcoholic fatty liver disease in a united states cohort of veterans. Clin. Gastroenterol. Hepatol. 2016, 14, 301-308.
9. Armstrong, M.J.; Adams, L.A.; Canbay, A.; Syn, W.K. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014, 59, 1174-1197.
10. Cicero, A.F.; Ertek, S. Metabolic and cardiovascular effects of berberine: From preclinical evidences to clinical trial results. Clin. Lipidol. 2009, 4, 553-563.
11. Wong, V.W.S.; Wong, G.L.H.; Tsang, S.W.C.; Fan, T.; Chu, W.C.W.; Woo, J.; Chan, A.W.H.; Choi, P.C.L.; Chim, A.M.L.; Lau, J.Y.W.; et al. High prevalence of colorectal neoplasm in patients with non-Alcoholic steatohepatitis. Gut 2011, 60, 829-836.
12. Lavine, J.E.; Schwimmer, J.B.; van Natta, M.L.; Molleston, J.P.; Murray, K.F.; Rosenthal, P.; Abrams, S.H.; Scheimann, A.O.; Sanyal, A.J.; Chalasani, N.; et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents the tonic randomized controlled trial. J. Am. Med. Assoc. 2011, 305, 1659-1668.
13. Gouni-Berthold, I.; Papanas, N.; Maltezos, E. The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with non-Alcoholic fatty liver disease. Curr. Pharm. Des. 2014, 20, 3705-3715.
14. Ratziu, V. Starting the battle to control non-Alcoholic steatohepatitis. Lancet 2015, 385, 922-924.
15. Neuschwander-Tetri, B.A.; Loomba, R.; Sanyal, A.J.; Lavine, J.E.; van Natta, M.L.; Abdelmalek, M.F.; Chalasani, N.; Dasarathy, S.; Diehl, A.M.; Hameed, B.; et al. Farnesoid x nuclear receptor ligand obeticholic acid for non-cirrhotic, non-Alcoholic steatohepatitis (flint): A multicentre, randomised, placebo-controlled trial. Lancet 2015, 385, 956-965.
16. Tillhon, M.; Ortiz, L.M.G.; Lombardi, P.; Scovassi, A.I. Berberine: New perspectives for old remedies. Biochem. Pharmacol. 2012, 84, 1260-1267.
17. Birdsall, T.C.; Kelly, G.S. Berberine: Therapeutic potential of an alkaloid found in several medicinal plants. Altern. Med. Rev. 1997, 2, 94-103.
18. Vuddanda, P.R.; Chakraborty, S.; Singh, S. Berberine: A potential phytochemical with multispectrum therapeutic activities. Expert Opin. Investig. Drugs 2010, 19, 1297-1307.
19. Kulkarni, S.K.; Dhir, A. Berberine: A plant alkaloid with therapeutic potential for central nervous system disorders. Phytother. Res. 2010, 24, 317-324.
20. Williams, K.H.; Shackel, N.A.; Gorrell, M.D.; McLennan, S.V.; Twigg, S.M. Diabetes and nonalcoholic fatty liver disease: A pathogenic duo. Endocr. Rev. 2013, 34, 84-129.
21. Chong, M.F.F.; Fielding, B.A.; Frayn, K.N. Mechanisms for the acute effect of fructose on postprandial lipemia. Am. J. Clin. Nutr. 2007, 85, 1511-1520.
22. Baidal, J.A.W.; Lavine, J.E. The intersection of nonalcoholic fatty liver disease and obesity. Sci. Transl. Med. 2016, 8.
23. Rinella, M.E. Nonalcoholic fatty liver disease a systematic review. J. Am. Med. Assoc. 2015, 313, 2263-2273.
24. Miele, L.; Valenza, V.; la Torre, G.; Montalto, M.; Cammarota, G.; Ricci, R.; Masciana, R.; Forgione, A.; Gabrieli, M.L.; Perotti, G.; et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49, 1877-1887.
25. Gaebele, E.; Dostert, K.; Hofmann, C.;Wiest, R.; Schoelmerich, J.; Hellerbrand, C.; Obermeier, F. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J. Hepatol. 2011, 55, 1391-1399.
26. Rivera, C.A.; Adegboyega, P.; van Rooijen, N.; Tagalicud, A.; Allman, M.;Wallace, M. Toll-like receptor-4 signaling and kupffer cells play pivotal roles in the pathogenesis of non-Alcoholic steatohepatitis. J. Hepatol. 2007, 47, 571-579.
27. Hu, Y.S.; Ehli, E.A.; Kittelsrud, J.; Ronan, P.J.; Munger, K.; Downey, T.; Bohlen, K.; Callahan, L.; Munson, V.; Jahnke, M.; et al. Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine 2012, 19, 861-867.
28. Derosa, G.; D'Angelo, A.; Bonaventura, A.; Bianchi, L.; Romano, D.; Maffioli, P. Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opin. Biol.Ther. 2013, 13, 475-482.
29. Yan, H.M.; Xia, M.F.; Wang, Y.; Chang, X.X.; Yao, X.Z.; Rao, S.X.; Zeng, M.S.; Tu, Y.F.; Feng, R.; Jia, W.P.; et al. Efficacy of berberine in patients with non-Alcoholic fatty liver disease. PLoS ONE 2015, 10, e0134172.
30. Liu, Y.; Zhang, L.; Song, H.Y.; Ji, G. Update on berberine in nonalcoholic fatty liver disease. Evid. Based Complement. Altern. Med. 2013, 2013.
31. Brown, M.S.; Goldstein, J.L. Selective versus total insulin resistance: A pathogenic paradox. Cell Metab. 2008, 7, 95-96.
32. Lee, Y.S.; Kim, W.S.; Kim, K.H.; Yoon, M.J.; Cho, H.J.; Shen, Y.; Ye, J.M.; Lee, C.H.; Oh, W.K.; Kim, C.T.; et al. Berberine, a natural plant product, activates amp-Activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55, 2256-2264.
33. Li, Y.; Xu, S.; Mihaylova, M.M.; Zheng, B.; Hou, X.; Jiang, B.; Park, O.; Luo, Z.; Lefai, E.; Shyy, J.Y.J.; et al. Ampk phosphorylates and inhibits srebp activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 2011, 13, 376-388.
34. Liu, X.; Li, G.; Zhu, H.; Huang, L.; Liu, Y.; Ma, C.; Qin, C. Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPS, LXR and PPAR transcriptional programs. Endocr. J. 2010, 57, 881-893.
35. Chen, Y.F.; Li, Y.; Wang, Y.W.; Wen, Y.; Sun, C.H. Berberine improves free-fatty-Acid-induced insulin resistance in l6 myotubes through inhibiting peroxisome proliferator-Activated receptor gamma and fatty acid transferase expressions. Metab. Clin. Exp. 2009, 58, 1694-1702.
36. Kong, W.J.; Zhang, H.; Song, D.Q.; Xue, R.; Zhao, W.; Wei, J.; Wang, Y.M.; Shan, N.; Zhou, Z.X.; Yang, P.; et al. Berberine reduces insulin resistance through protein kinase c-dependent up-regulation of insulin. Receptor expression. Metab. Clin. Exp. 2009, 58, 109-119.
37. Lou, T.J.; Zhang, Z.G.; Xi, Z.L.; Liu, K.; Li, L.; Liu, B.L.; Huang, F. Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. Inflammation 2011, 34, 659-667.
38. Xing, L.J.; Zhang, L.; Liu, T.; Hua, Y.Q.; Zheng, P.Y.; Ji, G. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur. J. Pharmacol. 2011, 668, 467-471.
39. Leng, S.H.; Lu, F.E.; Xu, L.J. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol. Sin. 2004, 25, 496-502.
40. Yamauchi, T.; Kamon, J.; Waki, H.; Terauchi, Y.; Kubota, N.; Hara, K.; Mori, Y.; Ide, T.; Murakami, K.; Tsuboyama-Kasaoka, N.; et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 7, 941-946.
41. Yamauchi, T.; Kamon, J.; Minokoshi, Y.; Ito, Y.;Waki, H.; Uchida, S.; Yamashita, S.; Noda, M.; Kita, S.; Ueki, K.; et al. Adiponectin stimulates glucose utilization and fatty-Acid oxidation by activating amp-Activated protein kinase. Nat. Med. 2002, 8, 1288-1295.
42. Waki, H.; Yamauchi, T.; Kamon, J.; Ito, Y.; Uchida, S.; Kita, S.; Hara, K.; Hada, Y.; Vasseur, F.; Froguel, P.; et al. Impaired multimerization of human adiponectin mutants associated with diabetes-Molecular structure and multimer formation of adiponectin. J. Biol. Chem. 2003, 278, 40352-40363.
43. Pajvani, U.B.; Du, X.L.; Combs, T.P.; Berg, A.H.; Rajala, M.W.; Schulthess, T.; Engel, J.; Brownlee, M.; Scherer, P.E. Structure-function studies of the adipocyte-secreted hormone ACRP30/adiponectin-Implications for metabolic regulation and bioactivity. J. Biol. Chem. 2003, 278, 9073-9085.
44. Li, Y.; Wang, P.C.; Zhuang, Y.; Lin, H.; Li, Y.H.; Liu, L.; Meng, Q.H.; Cui, T.; Liu, J.; Li, Z. Activation of ampk by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes. Febs Lett. 2011, 585, 1735-1740.
45. Kuo, C.L.; Chi, C.W.; Liu, T.Y. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 2004, 203, 127-137.
46. Guo, T.;Woo, S.L.; Guo, X.; Li, H.G.; Zheng, J.; Botchlett, R.; Liu, M.Y.; Pei, Y.; Xu, H.; Cai, Y.L.; et al. Berberine ameliorates hepatic steatosis and suppresses liver and adipose tissue inflammation in mice with diet-induced obesity. Sci. Rep. 2016, 6.
47. Wang, Z.-S.; Lu, F.-E.; Xu, L.-J.; Dong, H. Berberine reduces endoplasmic reticulum stress and improves insulin signal transduction in Hep G2 cells. Acta Pharmacol. Sin. 2010, 31, 578-584.
48. Zhang, Z.G.; Li, B.; Meng, X.J.; Yao, S.S.; Jin, L.N.; Yang, J.;Wang, J.Q.; Zhang, H.Z.; Zhang, Z.J.; Cai, D.S.; et al. Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. Sci. Rep. 2016, 6.
49. Larsen, P.J.; Jensen, P.B.; Sorensen, R.V.; Larsen, L.K.; Vrang, N.;Wulff, E.M.;Wassermann, K. Differential influences of peroxisonte proliferator-Activated receptors gamma and-on food intake and energy homeostasis. Diabetes 2003, 52, 2249-2259.
50. Yang, J.; Yin, J.H.; Gao, H.F.; Xu, L.X.; Wang, Y.; Xu, L.; Li, M. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid. Based Complement. Altern. Med. 2012, 2012.
51. Kahn, B.B.; Alquier, T.; Carling, D.; Hardie, D.G. Amp-Activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005, 1, 15-25.
52. Hardie, D.G. AMP-Activated/SNF1 protein kinases: Conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 2007, 8, 774-785.
53. Krishan, S.; Richardson, D.R.; Sahni, S. Adenosine monophosphate-Activated kinase and its key role in catabolism: Structure, regulation, biological activity, and pharmacological activation. Mol. Pharmacol. 2015, 87, 363-377.
54. Kim, W.S.; Lee, Y.S.; Cha, S.H.; Jeong, H.W.; Choe, S.S.; Lee, M.R.; Oh, G.T.; Park, H.S.; Lee, K.U.; Lane, M.D.; et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral ampk activity. Am. J. Physiol. Endocrinol. Metab. 2009, 296, E812-E819.
55. Brusq, J.M.; Ancellin, N.; Grondin, P.; Guillard, R.; Martin, S.; Saintillan, Y.; Issandou, M. Inhibition of lipid synthesis through activation of amp kinase: An additional mechanism for the hypolipidemic effects of berberine. J. Lipid Res. 2006, 47, 1281-1288.
56. Turner, N.; Li, J.Y.; Gosby, A.; To, S.W.C.; Cheng, Z.; Miyoshi, H.; Taketo, M.M.; Cooney, G.J.; Kraegen, E.W.; James, D.E.; et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: A mechanism for the action of berberine to activate AMP-Activated protein kinase and improve insulin action. Diabetes 2008, 57, 1414-1418.
57. Woods, A.; Johnstone, S.R.; Dickerson, K.; Leiper, F.C.; Fryer, L.G.D.; Neumann, D.; Schlattner, U.; Wallimann, T.; Carlson, M.; Carling, D. LKB1 is the upstream kinase in the amp-Activated protein kinase cascade. Curr. Biol. 2003, 13, 2004-2008.
58. Hawley, S.A.; Pan, D.A.; Mustard, K.J.; Ross, L.; Bain, J.; Edelman, A.M.; Frenguelli, B.G.; Hardie, D.G. Calmodulin-dependent protein kinase kinase-is an alternative upstream kinase for AMP-Activated protein kinase. Cell Metab. 2005, 2, 9-19.
59. Momcilovic, M.; Hong, S.-P.; Carlson, M. Mammalian TAK1 activates SNF1 protein kinase in yeast and phosphorylates AMP-Activated protein kinase in vitro. J. Biol. Chem. 2006, 281, 25336-25343.
60. Xu, M.; Xiao, Y.Y.; Yin, J.; Hou, W.L.; Yu, X.Y.; Shen, L.; Liu, F.; Wei, L.; Jia, W.P. Berberine promotes glucose consumption independently of AMP-Activated protein kinase activation. PLoS ONE 2014, 9, e103702.
61. Cao, S.J.; Zhou, Y.; Xu, P.X.; Wang, Y.; Yan, J.K.; Bin, W.; Qiu, F.; Kang, N. Berberine metabolites exhibit triglyceride-lowering effects via activation of AMP-Activated protein kinase in Hep G2 cells. J. Ethnopharmacol. 2013, 149, 576-582.
62. Teodoro, J.S.; Duarte, F.V.; Gomes, A.P.; Varela, A.T.; Peixoto, F.M.; Rolo, A.P.; Palmeira, C.M. Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: A possible role for SIRT3 activation. Mitochondrion 2013, 13, 637-646.
63. Gomes, A.P.; Duarte, F.V.; Nunes, P.; Hubbard, B.P.; Teodoro, J.S.; Varela, A.T.; Jones, J.G.; Sinclair, D.A.; Palmeira, C.M.; Rolo, A.P. Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochim. Biophys. Acta 2012, 1822, 185-195.
64. Larrouy, D.; Laharrague, P.; Carrera, G.; ViguerieBascands, N.; LeviMeyrueis, C.; Fleury, C.; Pecqueur, C.; Nibbelink, M.; Andre, M.; Casteilla, L.; et al. Kupffer cells are a dominant site of uncoupling protein 2 expression in rat liver. Biochem. Biophys. Res. Commun. 1997, 235, 760-764.
65. Baffy, G. Uncoupling protein-2 and non-Alcoholic fatty liver disease. Front. Biosci. 2005, 10, 2082-2096.
66. Jin, X.; Xiang, Z.; Chen, Y.-P.; Ma, K.-F.; Ye, Y.-F.; Li, Y.-M. Uncoupling protein and nonalcoholic fatty liver disease. Chin. Med. J. 2013, 126, 3151-3155.
67. Yang, S.; Zhu, H.; Li, Y.; Lin, H.; Gabrielson, K.; Trush, M.A.; Diehl, A.M. Mitochondrial adaptations to obesity-related oxidant stress. Arch. Biochem. Biophys. 2000, 378, 259-268.
68. Yang, Q.H.; Hu, S.P.; Zhang, Y.P.; Xie, W.N.; Li, N.; Ji, G.Y.; Qiao, N.L.; Lin, X.F.; Chen, T.Y.; Liu, H.T. Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-Alcoholic fatty liver disease in rats. Chin. J. Integr. Med. 2011, 17, 205-211.
69. Fares, R.; Petta, S.; Lombardi, R.; Grimaudo, S.; Dongiovanni, P.; Pipitone, R.; Rametta, R.; Fracanzani, A.L.; Mozzi, E.; Craxi, A.; et al. The UCP2-866 GA promoter region polymorphism is associated with nonalcoholic steatohepatitis. Liver Int. 2015, 35, 1574-1580.
70. Kong, W.J.; Wei, J.; Abidi, P.; Lin, M.H.; Inaba, S.; Li, C.; Wang, Y.L.; Wang, Z.Z.; Si, S.Y.; Pan, H.N.; et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 2004, 10, 1344-1351.
71. Backhed, F.; Ding, H.; Wang, T.; Hooper, L.V.; Koh, G.Y.; Nagy, A.; Semenkovich, C.F.; Gordon, J.I. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 2004, 101, 15718-15723.
72. Zhang, X.; Zhao, Y.; Zhang, M.; Pang, X.; Xu, J.; Kang, C.; Li, M.; Zhang, C.; Zhang, Z.; Zhang, Y.; et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS ONE 2012, 7, e42529.
73. Gu, L.; Li, N.; Li, Q.; Zhang, Q.; Wang, C.; Zhu, W.; Li, J. The effect of berberine in vitro on tight junctions in human CACO-2 intestinal epithelial cells. Fitoterapia 2009, 80, 241-248.
74. Gu, L.; Li, N.; Gong, J.; Li, Q.; Zhu, W.; Li, J. Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. J. Infect. Dis. 2011, 203, 1602-1612.
75. Abifadel, M.; Varret, M.; Rabes, J.P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003, 34, 154-156.
76. Cohen, J.C.; Boerwinkle, E.; Mosley, T.H.; Hobbs, H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 2006, 354, 1264-1272.
77. Liu, D.L.; Xu, L.J.; Dong, H.; Chen, G.; Huang, Z.Y.; Zou, X.; Wang, K.F.; Luo, Y.H.; Lu, F.E. Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia. Chin. J. Integr. Med. 2015, 21, 132-138.
78. Li, J.; Liu, Z.Z.; Guo, M.X.; Xu, K.J.; Jiang, M.; Lu, A.P.; Gao, X.Y. Metabolomics profiling to investigate the pharmacologic mechanisms of berberine for the treatment of high-fat diet-induced nonalcoholic steatohepatitis. Evid. Based Complement. Altern. Med. 2015, 2015.
79. Jiang, Z.J.; Liu, F.; Ong, E.S.; Li, S.F.Y. Metabolic profile associated with glucose and cholesterol lowering effects of berberine in sprague-dawley rats. Metabolomics 2012, 8, 1052-1068.
80. Yuan, X.L.; Wang, J.; Tang, X.Y.; Li, Y.X.; Xia, P.; Gao, X. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. J. Transl. Med. 2015, 13, 24.
81. Chang, X.X.; Yan, H.M.; Fei, J.; Jiang, M.H.; Zhu, H.G.; Lu, D.R.; Gao, X. Berberine reduces methylation of the mttp promoter and alleviates fatty liver induced by a high-fat diet in rats. J. Lipid Res. 2010, 51, 2504-2515.
82. Ma, C.; Kesarwala, A.H.; Eggert, T.; Medina-Echeverz, J.; Kleiner, D.E.; Jin, P.; Stroncek, D.F.; Terabe, M.; Kapoor, V.; ElGindi, M.; et al. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature 2016, 531, 253-257.
83. Perez-Rubio, K.G.; Gonzalez-Ortiz, M.; Martinez-Abundis, E.; Robles-Cervantes, J.A.; Espinel-Bermudez, M.C. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab. Syndr. Relat. Disord. 2013, 11, 366-369.
84. Wang, Y.X.; Kong, W.J.; Li, Y.H.; Tang, S.; Li, Z.; Li, Y.B.; Shan, Y.Q.; Bi, C.W.; Jiang, J.D.; Song, D.Q. Synthesis and structure-Activity relationship of berberine analogues in LDLR up-regulation and AMPK activation. Bioorg. Med. Chem. 2012, 20, 6552-6558.
85. Singh, I.P.; Mahajan, S. Berberine and its derivatives: A patent review (2009-2012). Expert Opin. Ther. Pat. 2013, 23, 215-231.
86. Jia, X.M.; Chen, Y.F.; Zidichouski, J.; Zhang, J.Z.; Sun, C.H.; Wang, Y.W. Co-Administration of berberine and plant stanols synergistically reduces plasma cholesterol in rats. Atherosclerosis 2008, 201, 101-107.